Affimed N.V.

NASDAQ:AFMD  
5.28
+0.10 (+1.93%)
Products, Strategic Combinations

Affimed, Roivant Sciences Announce Licensing And Strategic Collaboration Agreement To Develop And Commercialize Novel Innate Cell Engagers For Multiple Cancer Targets

Published: 11/09/2020 21:59 GMT
Affimed NV (AFMD) - Affimed and Roivant Sciences Announce Licensing and Strategic Collaboration Agreement to Develop and Commercialize Novel Innate Cell Engagers for Multiple Cancer Targets.
Affimed NV - to Receive $60 Million in Upfront Consideration and Up to an Additional $2 Billion in Future Milestones.
Affimed NV - to Be Responsible for All Preclinical Work Through Ind Filing.
Affimed NV - Roivant Will Be Responsible for Clinical Development and Commercialization Worldwide, Co Retains Option for Co-promotion.